Surgery and Anesthesia in Patients with Pulmonary Hypertension

Abstract

Pulmonary hypertension is characterized by right ventricular impairment and a reduced ability to compensate for hemodynamic insults. Consequently, surgery can be challenging but is increasingly considered in view of available specific therapies and improved longer term survival. Optimal management requires a multidisciplinary patient-centered approach involving surgeons, anesthetists, pulmonary hypertension clinicians, and intensivists. The optimal pathway involves risk:benefit assessment for the proposed operation, optimization of pulmonary hypertension and any comorbidities, the appropriate anesthetic approach for the specific procedure and patient, and careful monitoring and management in the postoperative period. Where patients are carefully selected and meticulously managed, good outcomes can be achieved.

Keywords

pulmonary hypertension - surgery - anesthesia

^* Equal contribution.

Publikationsverlauf

Artikel online veröffentlicht:
20. September 2023

• References

• 1 Humbert M, Kovacs G, Hoeper MM. et al; ESC/ERS Scientific Document Group. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2023; 61 (01) 2022
• 2 McGlothlin DP, Granton J, Klepetko W. et al. ISHLT consensus statement: Perioperative management of patients with pulmonary hypertension and right heart failure undergoing surgery. J Heart Lung Transplant 2022; 41 (09) 1135-1194
• 3 Ling Y, Johnson MK, Kiely DG. et al. Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am J Respir Crit Care Med 2012; 186 (08) 790-796
• 4 Condliffe R, Kiely DG, Gibbs JS. et al. Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2008; 177 (10) 1122-1127
• 5 Leber L, Beaudet A, Muller A. Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: identification of the most accurate estimates from a systematic literature review. Pulm Circ 2021; 11 (01) 2045894020977300
• 6 Hurdman J, Condliffe R, Elliot CA. et al. ASPIRE registry: assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre. Eur Respir J 2012; 39 (04) 945-955
• 7 Galiè N, Barberà JA, Frost AE. et al; AMBITION Investigators. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 2015; 373 (09) 834-844
• 8 Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol 2009; 53 (13) 1119-1126
• 9 Leung CC, Moondra V, Catherwood E, Andrus BW. Prevalence and risk factors of pulmonary hypertension in patients with elevated pulmonary venous pressure and preserved ejection fraction. Am J Cardiol 2010; 106 (02) 284-286
• 10 Shah AM, Claggett B, Sweitzer NK. et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. Circ Heart Fail 2014; 7 (05) 740-751
• 11 Vachiéry JL, Tedford RJ, Rosenkranz S. et al. Pulmonary hypertension due to left heart disease. Eur Respir J 2019; 53 (01) 1801897
• 12 Bermejo J, Yotti R, García-Orta R. et al; Sildenafil for Improving Outcomes after VAlvular Correction (SIOVAC) investigators. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial. Eur Heart J 2018; 39 (15) 1255-1264
• 13 Abraham AS, Cole RB, Green ID, Hedworth-Whitty RB, Clarke SW, Bishop JM. Factors contributing to the reversible pulmonary hypertension of patients with acute respiratory failure studies by serial observations during recovery. Circ Res 1969; 24 (01) 51-60
• 14 Kiely DG, Condliffe R. Assessing pulmonary hypertension severity in lung disease is a key step to improving outcomes: embrace resistance and don't be pressurised to go with the flow. Eur Respir J 2021; 58 (02) 58
• 15 Waxman A, Restrepo-Jaramillo R, Thenappan T. et al. Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease. N Engl J Med 2021; 384 (04) 325-334
• 16 Kim NH, Delcroix M, Jais X. et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 2019; 53 (01) 53
• 17 Vonk Noordegraaf A, Chin KM, Haddad F. et al. Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update. Eur Respir J 2019; 53 (01) 53
• 18 Price LC, Dimopoulos K, Marino P. et al. The CRASH report: emergency management dilemmas facing acute physicians in patients with pulmonary arterial hypertension. Thorax 2017; 72 (11) 1035-1045
• 19 Smilowitz NR, Armanious A, Bangalore S, Ramakrishna H, Berger JS. Cardiovascular outcomes of patients with pulmonary hypertension undergoing noncardiac surgery. Am J Cardiol 2019; 123 (09) 1532-1537
• 20 Ramakrishna G, Sprung J, Ravi BS, Chandrasekaran K, McGoon MD. Impact of pulmonary hypertension on the outcomes of noncardiac surgery: predictors of perioperative morbidity and mortality. J Am Coll Cardiol 2005; 45 (10) 1691-1699
• 21 Bauchmuller K, Condliffe R, Southern J. et al. Critical care outcomes in patients with pre-existing pulmonary hypertension: insights from the ASPIRE registry. ERJ Open Res 2021; 7 (02) 7
• 22 Hoeper MM, Kramer T, Pan Z. et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J 2017; 50 (02) 1700740
• 23 Boucly A, Weatherald J, Savale L. et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J 2017; 50 (02) 1700889
• 24 Benza RL, Gomberg-Maitland M, Miller DP. et al. The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest 2012; 141 (02) 354-362
• 25 Delcroix M, Staehler G, Gall H. et al. Risk assessment in medically treated chronic thromboembolic pulmonary hypertension patients. Eur Respir J 2018; 52 (05) 52
• 26 Benza RL, Farber HW, Frost A. et al. REVEAL risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguat. J Heart Lung Transplant 2018; 37 (07) 836-843
• 27 Rich S. The 6-minute walk test as a primary endpoint in clinical trials for pulmonary hypertension. J Am Coll Cardiol 2012; 60 (13) 1202-1203
• 28 Lewis RA, Billings CG, Hurdman JA. et al. Maximal exercise testing using the incremental shuttle walking test can be used to risk-stratify patients with pulmonary arterial hypertension. Ann Am Thorac Soc 2021; 18 (01) 34-43
• 29 Hadinnapola C, Bleda M, Haimel M. et al; NIHR BioResource–Rare Diseases Consortium; UK National Cohort Study of Idiopathic and Heritable PAH. Phenotypic characterization of EIF2AK4 mutation carriers in a large cohort of patients diagnosed clinically with pulmonary arterial hypertension. Circulation 2017; 136 (21) 2022-2033
• 30 Hoeper MM, Pausch C, Olsson KM. et al. COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. Eur Respir J 2022; 60 (01) 60
• 31 Benza RL, Gomberg-Maitland M, Elliott CG. et al. Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison with ESC/ERS-based risk assessment strategies. Chest 2019; 156 (02) 323-337
• 32 Benza RL, Kanwar MK, Raina A. et al. Development and validation of an abridged version of the REVEAL 2.0 risk score calculator, REVEAL Lite 2, for use in patients with pulmonary arterial hypertension. Chest 2021; 159 (01) 337-346
• 33 Deljou A, Sabov M, Kane GC. et al. Outcomes after noncardiac surgery for patients with pulmonary hypertension: a historical cohort study. J Cardiothorac Vasc Anesth 2020; 34 (06) 1506-1513
• 34 Aguirre MA, Lynch I, Hardman B. Perioperative management of pulmonary hypertension and right ventricular failure during noncardiac surgery. Adv Anesth 2018; 36 (01) 201-230
• 35 Minai OA, Yared JP, Kaw R, Subramaniam K, Hill NS. Perioperative risk and management in patients with pulmonary hypertension. Chest 2013; 144 (01) 329-340
• 36 Lewis RA, Johns CS, Cogliano M. et al. Identification of cardiac magnetic resonance imaging thresholds for risk stratification in pulmonary arterial hypertension. Am J Respir Crit Care Med 2020; 201 (04) 458-468
• 37 Smilowitz NR, Gupta N, Ramakrishna H, Guo Y, Berger JS, Bangalore S. Perioperative major adverse cardiovascular and cerebrovascular events associated with noncardiac surgery. JAMA Cardiol 2017; 2 (02) 181-187
• 38 Tartavoulle T, Bonanno LS, Hall S. Perioperative considerations for patients diagnosed with pulmonary hypertension undergoing noncardiac surgery. J Perianesth Nurs 2019; 34 (02) 240-249
• 39 Badagliacca R, Papa S, Poscia R. et al. The added value of cardiopulmonary exercise testing in the follow-up of pulmonary arterial hypertension. J Heart Lung Transplant 2019; 38 (03) 306-314
• 40 Davenport DL, Ferraris VA, Hosokawa P, Henderson WG, Khuri SF, Mentzer Jr RM. Multivariable predictors of postoperative cardiac adverse events after general and vascular surgery: results from the patient safety in surgery study. J Am Coll Surg 2007; 204 (06) 1199-1210
• 41 Lewis RA, Thompson AAR, Billings CG. et al. Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension. Eur Respir J 2020; 55 (06) 2000041
• 42 Hoeper MM, Dwivedi K, Pausch C. et al. Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis. Lancet Respir Med 2022; 10 (10) 937-948
• 43 Haque A, Kiely DG, Kovacs G, Thompson AAR, Condliffe R. Pulmonary hypertension phenotypes in patients with systemic sclerosis. Eur Respir Rev 2021; 30 (161) 30
• 44 Kiely DG, Levin D, Hassoun P. et al. EXPRESS: statement on imaging and pulmonary hypertension from the Pulmonary Vascular Research Institute (PVRI). Pulm Circ 2019; 9 (03) 2045894019841990
• 45 England TRCoSo. The higher risk general surgical patient: towards improved care for a forgotten group. 2011 Zugriff am 08. August 2023 unter: https://www.rcseng.ac.uk/library-and-publications/rcs-publications/docs/the-higher-risk-general-surgical-patient/
• 46 Price LC, Martinez G, Brame A. et al. Perioperative management of patients with pulmonary hypertension undergoing non-cardiothoracic, non-obstetric surgery: a systematic review and expert consensus statement. Br J Anaesth 2021; 126 (04) 774-790
• 47 Atkinson TM, Giraud GD, Togioka BM, Jones DB, Cigarroa JE. Cardiovascular and ventilatory consequences of laparoscopic surgery. Circulation 2017; 135 (07) 700-710
• 48 Jung KT, Kim SH, Kim JW, So KY. Bradycardia during laparoscopic surgery due to high flow rate of CO2 insufflation. Korean J Anesthesiol 2013; 65 (03) 276-277
• 49 Kiely DG, Cargill RI, Lipworth BJ. Effects of hypercapnia on hemodynamic, inotropic, lusitropic, and electrophysiologic indices in humans. Chest 1996; 109 (05) 1215-1221
• 50 Donaldson AJ, Thomson HE, Harper NJ, Kenny NW. Bone cement implantation syndrome. Br J Anaesth 2009; 102 (01) 12-22
• 51 Ritter J, Hubert J, Kniep I, Beil FT, Rolvien T, Püschel K. Pulmonary cement embolism is frequently observed but not a contributing factor for death in patients with cemented total hip and knee arthroplasty: a postmortem study. Int Orthop 2022; 46 (06) 1225-1232
• 52 Qi X, Zhang Y, Pan J, Ma L, Wang L, Wang J. Effect of bone cement implantation on haemodynamics in elderly patients and preventive measure in cemented hemiarthroplasty. BioMed Res Int 2015; 2015: 568019
• 53 Memtsoudis SG, Ma Y, Chiu YL, Walz JM, Voswinckel R, Mazumdar M. Perioperative mortality in patients with pulmonary hypertension undergoing major joint replacement. Anesth Analg 2010; 111 (05) 1110-1116
• 54 Seyfarth HJ, Gille J, Sablotzki A. et al. Perioperative management of patients with severe pulmonary hypertension in major orthopedic surgery: experience-based recommendations. GMS Interdiscip Plast Reconstr Surg DGPW 2015; 4: Doc03
• 55 Wardle M, Nair A, Saunders S. et al. Elective lower limb orthopedic arthroplasty surgery in patients with pulmonary hypertension. Pulm Circ 2022; 12 (01) e12019
• 56 Yentis SM, Steer PJ, Plaat F. Eisenmenger's syndrome in pregnancy: maternal and fetal mortality in the 1990s. Br J Obstet Gynaecol 1998; 105 (08) 921-922
• 57 Weiss BM, Zemp L, Seifert B, Hess OM. Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996. J Am Coll Cardiol 1998; 31 (07) 1650-1657
• 58 Bonnin M, Mercier FJ, Sitbon O. et al. Severe pulmonary hypertension during pregnancy: mode of delivery and anesthetic management of 15 consecutive cases. Anesthesiology 2005; 102 (06) 1133-1137 , discussion 5A–6A
• 59 Bédard E, Dimopoulos K, Gatzoulis MA. Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension?. Eur Heart J 2009; 30 (03) 256-265
• 60 Kiely DG, Condliffe R, Webster V. et al. Improved survival in pregnancy and pulmonary hypertension using a multiprofessional approach. BJOG 2010; 117 (05) 565-574
• 61 Kamp JC, von Kaisenberg C, Greve S. et al. Pregnancy in pulmonary arterial hypertension: midterm outcomes of mothers and offspring. J Heart Lung Transplant 2021; 40 (03) 229-233
• 62 Jaïs X, Olsson KM, Barbera JA. et al. Pregnancy outcomes in pulmonary arterial hypertension in the modern management era. Eur Respir J 2012; 40 (04) 881-885
• 63 Hemnes AR, Kiely DG, Cockrill BA. et al. Statement on pregnancy in pulmonary hypertension from the Pulmonary Vascular Research Institute. Pulm Circ 2015; 5 (03) 435-465
• 64 Singh A, Siddiqui MT, Al-Yaman W. et al. Utility of endoscopy in hospitalized patients with gastrointestinal hemorrhage and pulmonary hypertension. Dig Dis Sci 2021; 66 (12) 4159-4168
• 65 Lai C, Savale L, Boytchev I. et al. Risks and outcomes of gastrointestinal endoscopy with anaesthesia in patients with pulmonary hypertension. Br J Anaesth 2020; 125 (06) e466-e468
• 66 Diaz-Fuentes G, Bajantri B, Adrish M. Safety of bronchoscopy in patients with echocardiographic evidence of pulmonary hypertension. Respiration 2016; 92 (03) 182-187
• 67 Ishiwata T, Abe M, Kasai H. et al. Safety of diagnostic flexible bronchoscopy in patients with echocardiographic evidence of pulmonary hypertension. Respir Investig 2019; 57 (01) 73-78
• 68 Schulman LL, Smith CR, Drusin R, Rose EA, Enson Y, Reemtsma K. Utility of airway endoscopy in the diagnosis of respiratory complications of cardiac transplantation. Chest 1988; 93 (05) 960-967
• 69 Kaye AD, Hoover JM, Kaye AJ. et al. Morphine, opioids, and the feline pulmonary vascular bed. Acta Anaesthesiol Scand 2008; 52 (07) 931-937
• 70 Ouédraogo N, Mounkaïla B, Crevel H, Marthan R, Roux E. Effect of propofol and etomidate on normoxic and chronically hypoxic pulmonary artery. BMC Anesthesiol 2006; 6: 2
• 71 Green DW. Cardiac output decrease and propofol: what is the mechanism?. Br J Anaesth 2015; 114 (01) 163-164
• 72 Colvin MP, Savege TM, Newland PE. et al. Cardiorespiratory changes following induction of anaesthesia with etomidate in patients with cardiac disease. Br J Anaesth 1979; 51 (06) 551-556
• 73 Jabre P, Combes X, Lapostolle F. et al; KETASED Collaborative Study Group. Etomidate versus ketamine for rapid sequence intubation in acutely ill patients: a multicentre randomised controlled trial. Lancet 2009; 374 (9686) 293-300
• 74 Gooding JM, Dimick AR, Tavakoli M, Corssen G. A physiologic analysis of cardiopulmonary responses to ketamine anesthesia in noncardiac patients. Anesth Analg 1977; 56 (06) 813-816
• 75 Tweed WA, Minuck M, Mymin D. Circulatory responses to ketamine anesthesia. Anesthesiology 1972; 37 (06) 613-619
• 76 Friesen RH, Twite MD, Nichols CS. et al. Hemodynamic response to ketamine in children with pulmonary hypertension. Paediatr Anaesth 2016; 26 (01) 102-108
• 77 Hickey PR, Hansen DD, Cramolini GM, Vincent RN, Lang P. Pulmonary and systemic hemodynamic responses to ketamine in infants with normal and elevated pulmonary vascular resistance. Anesthesiology 1985; 62 (03) 287-293
• 78 Schulte-Sasse U, Hess W, Tarnow J. Pulmonary vascular responses to nitrous oxide in patients with normal and high pulmonary vascular resistance. Anesthesiology 1982; 57 (01) 9-13
• 79 Blaudszun G, Morel DR. Superiority of desflurane over sevoflurane and isoflurane in the presence of pressure-overload right ventricle hypertrophy in rats. Anesthesiology 2012; 117 (05) 1051-1061
• 80 Rich S, Gubin S, Hart K. The effects of phenylephrine on right ventricular performance in patients with pulmonary hypertension. Chest 1990; 98 (05) 1102-1106
• 81 Kerbaul F, Rondelet B, Motte S. et al. Effects of norepinephrine and dobutamine on pressure load-induced right ventricular failure. Crit Care Med 2004; 32 (04) 1035-1040
• 82 Kwak YL, Lee CS, Park YH, Hong YW. The effect of phenylephrine and norepinephrine in patients with chronic pulmonary hypertension*. Anaesthesia 2002; 57 (01) 9-14
• 83 Hirsch LJ, Rooney MW, Wat SS, Kleinmann B, Mathru M. Norepinephrine and phenylephrine effects on right ventricular function in experimental canine pulmonary embolism. Chest 1991; 100 (03) 796-801
• 84 Bandyopadhyay D, Lai C, Pulido JN, Restrepo-Jaramillo R, Tonelli AR, Humbert M. Perioperative approach to precapillary pulmonary hypertension in non-cardiac non-obstetric surgery. Eur Respir Rev 2021; 30 (162) 30
• 85 Jones RK, Caldwell JE, Brull SJ, Soto RG. Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology 2008; 109 (05) 816-824
• 86 Strumpher J, Jacobsohn E. Pulmonary hypertension and right ventricular dysfunction: physiology and perioperative management. J Cardiothorac Vasc Anesth 2011; 25 (04) 687-704
• 87 Kruthiventi SC, Kane GC, Sprung J, Weingarten TN, Warner ME. Postoperative pulmonary complications in contemporary cohort of patients with pulmonary hypertension. Bosn J Basic Med Sci 2019; 19 (04) 392-399
• 88 Condliffe R, Kiely DG. Critical care management of pulmonary hypertension. BJA Educ 2017; 17: 228-234
• 89 Minai OA, Venkateshiah SB, Arroliga AC. Surgical intervention in patients with moderate to severe pulmonary arterial hypertension. Conn Med 2006; 70 (04) 239-243
• 90 Lai HC, Lai HC, Wang KY, Lee WL, Ting CT, Liu TJ. Severe pulmonary hypertension complicates postoperative outcome of non-cardiac surgery. Br J Anaesth 2007; 99 (02) 184-190
• 91 Price LC, Montani D, Jaïs X. et al. Noncardiothoracic nonobstetric surgery in mild-to-moderate pulmonary hypertension. Eur Respir J 2010; 35 (06) 1294-1302
• 92 Kaw R, Pasupuleti V, Deshpande A, Hamieh T, Walker E, Minai OA. Pulmonary hypertension: an important predictor of outcomes in patients undergoing non-cardiac surgery. Respir Med 2011; 105 (04) 619-624
• 93 Meyer S, McLaughlin VV, Seyfarth HJ. et al. Outcomes of noncardiac, nonobstetric surgery in patients with PAH: an international prospective survey. Eur Respir J 2013; 41 (06) 1302-1307
• 94 Bennett JM, Ehrenfeld JM, Markham L, Eagle SS. Anesthetic management and outcomes for patients with pulmonary hypertension and intracardiac shunts and Eisenmenger syndrome: a review of institutional experience. J Clin Anesth 2014; 26 (04) 286-293
• 95 Kiely DG, Elliot CA, Sabroe I, Condliffe R. Pulmonary hypertension: diagnosis and management. BMJ 2013; 346: f2028